Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Cytochrome P450 4F11 (CYP4F11) is implicated in cancer progression.
• Stearoyl-CoA desaturase (SCD) is essential for tumor growth.
• Targeting cancer-specific vulnerabilities is a key therapeutic strategy.

Purpose of the Study:

• To develop novel N-acyl benzothiazoles as selective cancer therapeutics.
• To investigate a prodrug strategy for tumor-specific activation.
• To evaluate the efficacy of SCD inhibition in a preclinical cancer model.

Main Methods:

• Synthesis and characterization of N-acyl benzothiazole derivatives.
• In vitro cytotoxicity assays against cancer cell lines with varying CYP4F11 expression.
• In vivo proof-of-concept studies in mice using a lead prodrug candidate.
• Pharmacokinetic and pharmacodynamic assessments.

Main Results:

• A series of N-acyl benzothiazoles demonstrated potent and selective cytotoxicity against CYP4F11-expressing cancer cells.
• The prodrug form was efficiently metabolized by cancer cells into an active SCD inhibitor.
• (R)-27, a lead compound, exhibited balanced potency, solubility, and lipophilicity, enabling in vivo studies.
• Tumor growth was arrested following prodrug administration, with activation occurring within the tumor microenvironment.

Conclusions:

• N-acyl benzothiazoles represent a promising class of anticancer agents targeting CYP4F11.
• A tumor-activated prodrug strategy can effectively exploit SCD essentiality for cancer therapy.
• This approach offers potential for targeted cancer treatment with reduced systemic toxicity.